Tacrolimus Versus Prednisolone for the Treatment of Minimal Change Disease

• Status: Completed
• Trial end date: 2019-10-10
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the effectiveness of tacrolimus (prograf) versus prednisolone for the treatment of nephrotic syndrome secondary to minimal change disease.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Imperial College Healthcare NHS Trust
• Treatments: Methylprednisolone; Methylprednisolone acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate; Tacrolimus

Criteria

Inclusion Criteria:

• Patients with nephrotic syndrome (hypoalbuminaemia and protein creatinine ratio (PCR) > 100units), secondary to minimal change disease.

• Age over 18.

Exclusion Criteria:

• Hepatitis B, hepatitis C or HIV infection.

• Untreated infection.

• Females who are pregnant, breast feeding, or at risk of pregnancy and not using a medically acceptable form of contraception.

• Patients who have been treated with immunosuppression over the last 18 months.

• Patients who have had more than 3 relapses of nephrotic syndrome within 5 years.

• Any condition judged by the investigator that would cause the study to be detrimental to the patient.